Reyvow Dosage: Form, Strengths, How to Use, and More

Medical note: This article is for general education only and is not a substitute for medical advice. Reyvow is a prescription medicine for adults, and dosing decisions should always be made by a licensed healthcare professional.

Migraine has a special talent for arriving at the worst possible time: during work, before a family dinner, in the middle of errands, or exactly when you thought the day was finally behaving itself. Reyvow, the brand name for lasmiditan, was developed as an acute migraine treatment for adults who need a prescription option when an attack begins. It is not a daily prevention pill, not a casual pain reliever, and definitely not something to “experiment” with because a migraine has made life feel like a drum solo inside your head.

This guide explains Reyvow dosage, available forms and strengths, how it is generally described in U.S. prescribing information, important safety warnings, missed-dose confusion, driving restrictions, and practical experience-based tips for discussing treatment with a healthcare provider. It also includes an important 2026 availability update: Lilly has announced that U.S. distribution of Reyvow is scheduled to end on May 31, 2026, with limited product available afterward until remaining supply is exhausted.

What Is Reyvow?

Reyvow is a prescription oral medication used for the acute treatment of migraine with or without aura in adults. “Acute treatment” means it is used when a migraine attack happens. It is not approved to prevent migraines, reduce the number of migraine days over time, or replace a long-term migraine prevention plan.

The active ingredient in Reyvow is lasmiditan. It belongs to a drug class often called ditans. Unlike triptans, which are older and commonly used migraine medicines, lasmiditan acts mainly on serotonin 5-HT1F receptors and is not designed to narrow blood vessels. That difference is one reason clinicians may have considered Reyvow for certain adults who needed an acute migraine option and had specific medical considerations. However, the medicine also carries important central nervous system warnings, especially related to dizziness, sleepiness, and driving impairment.

Reyvow Form and Strengths

Reyvow comes as an oral tablet. U.S. labeling describes the available tablet strengths as:

• 50 mg tablet
• 100 mg tablet

The labeled dose options are commonly described as 50 mg, 100 mg, or 200 mg, depending on what a healthcare provider prescribes. The 200 mg dose may involve taking two 100 mg tablets, but patients should never adjust the number of tablets on their own. With migraine medicine, “more” does not automatically mean “better.” Sometimes it just means more side effects, more risk, and more reasons your doctor will raise an eyebrow.

Typical Reyvow Dosage Overview

U.S. prescribing information lists Reyvow dosing as 50 mg, 100 mg, or 200 mg by mouth as needed for a migraine attack. The key phrase is “as prescribed.” A healthcare provider considers the person’s migraine history, other medications, side effect risk, medical conditions, response to prior treatments, and safety needs before choosing a dose.

One of the most important dosage rules is that no more than one dose should be taken within 24 hours. A second dose for the same migraine attack has not been shown to be effective. This is different from some other migraine medicines where repeat dosing may be part of the plan. Reyvow has its own rulebook, and the rulebook is not shy about the 24-hour limit.

Can Reyvow Be Used for Every Migraine?

The safety of treating an average of more than four migraine attacks in a 30-day period has not been established in U.S. labeling. That does not mean a person with frequent migraines is out of options. It means frequent attacks should be discussed with a healthcare provider because the overall treatment plan may need adjusting. People with frequent migraine days may need preventive therapy, trigger tracking, lifestyle support, or another acute medication strategy.

How Reyvow Is Generally Taken

Reyvow tablets are described as tablets taken by mouth. Labeling states that the tablets should be swallowed whole and should not be split, crushed, or chewed. Reyvow may be taken with or without food. For some people, taking medicine during a migraine can be tricky because nausea may already be part of the attack. That is a good reason to talk with a clinician about a full migraine action plan, not just the tablet itself.

Because Reyvow can cause significant sleepiness, dizziness, and impaired alertness, the timing of a dose matters. This medicine is not a “take it and drive to work” kind of treatment. It requires planning, especially for anyone who drives, operates machinery, supervises others, works with tools, or has responsibilities that require quick reactions.

The 8-Hour Driving Warning

The most famous Reyvow warning is also the one people should not treat as fine print: do not drive or operate machinery for at least 8 hours after taking Reyvow. This warning applies even if the person feels awake enough to drive. That last part matters because some people may not accurately judge their own impairment after taking the medication.

In real life, this means Reyvow can be difficult to fit into a busy day. If someone has to drive children, commute, operate workplace equipment, or get themselves home, they need to discuss timing and alternatives with their healthcare provider. Migraine treatment should reduce chaos, not create a new transportation puzzle with bonus dizziness.

Important Safety Considerations

Like all prescription medicines, Reyvow has possible side effects and risks. Commonly discussed side effects include dizziness, fatigue, sleepiness, tingling or numb sensations, and nausea. Some people may feel unusually tired or mentally slowed after a dose. Because migraine itself can also cause brain fog, light sensitivity, nausea, and fatigue, it can be hard to separate the migraine from the medication without tracking symptoms.

Reyvow may also interact with alcohol, sedatives, sleep medicines, anxiety medicines, certain antidepressants, and other drugs that affect the central nervous system or serotonin. People should give their healthcare provider and pharmacist a complete medication list, including prescription drugs, over-the-counter medicines, supplements, and herbal products. The humble “I only take it sometimes” pill still belongs on that list.

Controlled Substance Status

Lasmiditan is a federally controlled substance in the United States. That means prescriptions and refills may be handled differently from non-controlled medications. Patients should not share Reyvow with anyone else, even if that person also has migraines. Sharing prescription medication is unsafe, and with controlled substances, it can create legal and medical problems.

Who Should Talk Carefully With a Doctor Before Using Reyvow?

A healthcare provider should know if a patient has a history of liver problems, heart rate or blood pressure concerns, substance use disorder, depression, unusual reactions to migraine medicines, or use of medications that may cause sedation. People who are pregnant, planning pregnancy, or breastfeeding should also discuss risks and benefits with a clinician.

Reyvow is approved for adults, not children. Anyone under 18 with migraines should be evaluated by a healthcare professional who can recommend age-appropriate treatment options. Migraine in teens is real and deserves care, but adult prescription dosing information should not be used as a shortcut.

What If Reyvow Does Not Work?

If a prescribed dose does not relieve a migraine, the person should not simply take more Reyvow that day. U.S. labeling states that a second dose has not been shown to be effective for the same migraine attack, and no more than one dose should be taken in 24 hours. Instead, the next step is to contact a healthcare provider. A migraine plan may include a different acute medication, a nausea treatment, a rescue plan, or preventive therapy if attacks happen often.

It is also worth checking whether the medicine was taken at the right point in the migraine attack, whether nausea interfered, whether other triggers were involved, and whether the diagnosis is still accurate. Not every severe headache is migraine, and not every migraine behaves politely enough to follow the textbook.

Reyvow Availability Update for 2026

As of 2026, patients and healthcare providers should be aware that Lilly has announced the discontinuation of Reyvow distribution in the United States, with distribution scheduled to end on May 31, 2026. After that date, limited supply may remain available only until existing product is exhausted.

This does not mean patients should stop a prescribed medication without medical guidance. It does mean anyone currently using Reyvow should contact their healthcare provider soon to discuss alternatives. Options may include other acute migraine treatments, preventive medications, non-drug strategies, or a revised migraine action plan. Waiting until the last tablet is gone is a classic migraine-management plot twist best avoided.

Reyvow Dosage Questions to Ask a Healthcare Provider

Because Reyvow dosing is individualized, patients can prepare for an appointment by asking practical questions such as:

• Which dose was prescribed, and why?
• What should I do if the migraine returns the same day?
• What side effects should make me call the office?
• How should I plan around the 8-hour driving restriction?
• Can Reyvow be used with my other migraine medicines?
• How many migraine attacks per month should I treat before we revisit the plan?
• What should I switch to if Reyvow becomes unavailable?

These questions help turn a prescription into a usable plan. Migraine care is not just about what is written on the bottle. It is about what happens at 2:17 p.m. when the lights are too bright, the meeting is in ten minutes, and your brain has apparently filed a formal complaint.

How to Track Reyvow Use Safely

A migraine diary can be very helpful. Patients can track the date and time of the migraine, symptoms, possible triggers, dose prescribed, time the medication was taken, side effects, relief after two hours, and whether the migraine returned later. This information helps clinicians decide whether the current plan is working or whether another approach may be better.

Tracking also helps identify medication-overuse patterns. Using acute migraine medicine too often can sometimes contribute to worsening headache patterns, depending on the medication and the person’s overall treatment plan. If attacks are frequent, preventive care may be more effective than repeatedly fighting migraines one at a time like tiny neurological house fires.

Experience-Based Tips: What Reyvow Use May Feel Like in Real Life

For many people, the most memorable part of a Reyvow treatment plan is not the tablet size or the prescription label. It is the planning. A medication with an 8-hour driving restriction asks a patient to think ahead in a way that some other migraine treatments may not. That can be frustrating, especially because migraines rarely send calendar invites. A person may wake up with pain, feel symptoms build during work, or notice aura while running errands. Suddenly, the question is not only “Will this medicine help?” but also “Can I safely clear the next eight hours?”

One realistic experience is the “evening dose” scenario. Some patients may find that a medicine with sedation warnings is easier to fit into a late-day plan, when they are already home and do not need to drive. In that situation, the practical steps may include dimming lights, drinking water if tolerated, eating a small snack if nausea allows, putting away work responsibilities, and letting another adult know they may be resting. The goal is not to turn migraine treatment into a spa day. Migraine is not a scented candle. But a calmer environment can make it easier to monitor symptoms and avoid unsafe activities.

Another experience is the “workday problem.” A person who drives to work or operates equipment may realize Reyvow is not convenient for daytime attacks. That does not mean they failed the medication. It means the treatment may not match their daily responsibilities. This is exactly the kind of detail worth discussing with a clinician. A migraine medicine can be clinically appropriate on paper but awkward in real life, and real life gets a vote.

Some people may also experience dizziness, heaviness, fatigue, or a “slowed down” feeling. That can be unsettling if they expected a standard painkiller experience. Reyvow is not a typical over-the-counter headache medicine, and its central nervous system effects are part of why the safety warnings are emphasized. Patients should avoid alcohol and other sedating substances unless their healthcare provider specifically says otherwise. They should also avoid making important decisions, cooking with risky equipment, climbing ladders, or doing anything that requires sharp coordination after taking a sedating migraine medication.

A useful habit is creating a migraine action card. This can list the prescribed medication plan, driving restrictions, emergency symptoms, the doctor’s contact information, and backup support such as a family member, rideshare plan, or workplace accommodation. For someone with unpredictable migraines, this card can reduce decision-making during an attack, when brain fog may make even simple choices feel like solving a crossword underwater.

Because Reyvow is being discontinued in the United States, the experience section now has one more practical layer: transition planning. Patients who still have Reyvow should not wait until supply becomes difficult to find. A healthcare provider can help compare alternatives based on medical history, attack frequency, cardiovascular considerations, nausea, insurance coverage, and daily responsibilities. The best migraine plan is not just scientifically sound; it is usable on a Tuesday afternoon when the world is loud, the screen is too bright, and the couch is calling like it has breaking news.

Conclusion

Reyvow dosage information centers on a few key facts: it is a prescription tablet for the acute treatment of migraine with or without aura in adults; labeled dose options include 50 mg, 100 mg, and 200 mg; no more than one dose should be taken in 24 hours; and patients should not drive or operate machinery for at least 8 hours after taking it. It is not a preventive migraine medication, and its safety has not been established for treating more than an average of four migraine attacks in 30 days.

The most important takeaway is that Reyvow is not a casual “grab and go” headache pill. It requires medical supervision, careful timing, and a serious respect for the driving warning. With U.S. distribution scheduled to end in 2026, patients currently prescribed Reyvow should speak with their healthcare provider about safe alternatives and a transition plan.